## 4 Discussion  
The dietary management of NAFLD is associated mainly with a low-energy diet, as body mass reduction is the most effective way to reduce liver steatosis [47]. It is indicated that a body mass reduction of 7-10% resolves steatohepatitis and improves fibrosis, confirmed by liver histopathology [36; 48]. In this conducted study, body mass reduction was not observed in spite of the fact that patients received the recommendation of a low-energy diet, which was encouraged to be followed every 2 weeks. However, it should be emphasized that body mass reduction is a long-term process, and, in the case of NAFLD patients, it is commonly unsuccessful [49]. As a result, the risk of fibrosis caused by NASH progression still exists [50]. Within the possible reasons of unsuccessful body mass reduction, caused by not following the low-energy diet, there may be an association with socializing and spending time with friends. This results from the fact that the study was conducted in the period of spring and summer, which is typically associated with barbecue socializing, indicated \begin{table}
\begin{tabular}{c c c c c c} \hline \hline \multirow{2}{*}{**Parameter**} & \multicolumn{3}{c}{**Baseline**} & \multicolumn{3}{c}{**After 3 Months of Intervention**} & \multirow{2}{*}{\(p\)**\({}^{**}\)**} \\  & **Mean \(\pm\) SD** & **Median (Min-Max)** & & & \\ \hline Triglycerides (mg/dL) & 140.36 \(\pm\) 14.92 & 138.95 (116.98–185.52) & 110.04 \(\pm\) 37.23 & 127.26 (64.03–166.99) \({}^{*}\) & 0.0017 \\ Total cholesterol (mg/dL) & 153.73 \(\pm\) 39.94 & 143.61 (105.73–252.26) & 145.78 \(\pm\) 39.74 & 135.72 (91.24–234.65) & 0.5374 \\ HDL-C (mg/dL) & 32.27 \(\pm\) 11.13 & 30.01 (19.56–66.66) \({}^{*}\) & 29.73 \(\pm\) 7.56 & 28.11 (18.11–50.23) & 0.5457 \\ LDL-C (mg/dL) & 93.38 \(\pm\) 35.15 & 88.99 (40.21–171.34) & 94.05 \(\pm\) 37.02 & 82.99 (51.3–179.70) & 0.5544 \\ ALT (U/L) & 11.36 \(\pm\) 5.78 & 11.90 (2.09–21.59) & 13.66 \(\pm\) 6.43 & 13.21(7.33–34.48) \({}^{*}\) & 0.4857 \\ GGT (U/L) & 23.03 \(\pm\) 12.87 & 20.28 (9.18–58.75) \({}^{*}\) & 12.77 \(\pm\) 5.24 & 11.55 (7.00–27.89) \({}^{*}\) & 0.0008 \\ \hline HDL-C—high-density lipoprotein cholesterol; LDL–low-density lipoprotein cholesterol; ALT—alanine aminotransferase; GGT—gamma-glutamyltransferase; * nonparametric distribution (Shapiro–Wilk test; \(p\leq 0.05\)); ** compared while using t-Student test or Mann–Whitney test (based on distribution).** & & \\ \hline \hline \end{tabular}
\end{table} 
Table 10: The biochemical parameters of the participants at baseline and after 3 months of intervention. \begin{table}
\begin{tabular}{c c c c c c} \hline \hline \multirow{2}{*}{**Parameter**} & \multicolumn{3}{c}{**Baseline**} & \multicolumn{3}{c}{**After 3 Months of Intervention**} & \multirow{2}{*}{\(p\)**\({}^{**}\)**} \\  & **Mean \(\pm\) SD** & **Median (Min–Max)** & & & \\ \hline Total energy expenditure (kcal) & 1617.9 \(\pm\) 431.9 & 1522.0 (1266.3–2704.0) \({}^{*}\) & 1624.6 \(\pm\) 239.5 & 1628.0 (1250.7–1931.5) & 0.5317 \\ Physical activity duration (min) & 55.7 \(\pm\) 73.4 & 38.7 (10.7–247.7) \({}^{*}\) & 50.2 \(\pm\) 13.9 & 52.7 (30.7–70.0) & 0.1358 \\ Lying down duration (min) & 211.4 \(\pm\) 37.2 & 227.3 (154.3–248.0) \({}^{*}\) & 220.7 \(\pm\) 68.9 & 207.0 (110.3–345.0) & 0.8099 \\ Active energy expenditure (kcal) & 379.4 \(\pm\) 509.0 & 281.3 (58.0–1705.7) \({}^{*}\) & 327.9 \(\pm\) 100.5 & 324.3 (181.0–474.3) & 0.2685 \\ Number of steps & 4482 \(\pm\) 2033 & 3785 (2380-8065) & 5512 \(\pm\) 2308 & 5792 (2356-8326) & 0.3142 \\ Sleep duration (min) & 168.9 \(\pm\) 34.0 & 159.3 (112.0–224.0) & 170.0 \(\pm\) 48.9 & 165.5 (81.3–255.0) & 0.9568 \\ Average METs & 1.02 \(\pm\) 0.41 & 1.00 (0.87–1.17) & 1.34 \(\pm\) 0.12 & 1.35 (1.10–1.47) & \(\textless\)0.0001 \\ \hline MET—metabolic equivalent of task; \({}^{*}\) nonparametric distribution (Shapiro–Wilk test; \(p\leq 0.05\)); \({}^{**}\) compared while using t-Student test or Mann–Whitney test (based on distribution). & & \\ \hline \hline \end{tabular}
\end{table}